REGN5069 / Regeneron - LARVOL DELTA

Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain. (PubMed, Neurobiol Pain) - P1, P2 | "In addition to possible differences in GFRα3 biology between mice and humans, we highlight here differences in experimental parameters that could have contributed to a different profile of efficacy in mouse models versus human OA pain. Additional research is required to more fully evaluate any potential role of GFRα3 in human pain."

Clinical • Journal • Preclinical • CNS Disorders • Immunology • Inflammation • Migraine • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee (clinicaltrials.gov) - P2; N=259; Terminated; Sponsor: Regeneron Pharmaceuticals; Trial completion date: Feb 2021 ➔ Oct 2020; Active, not recruiting ➔ Terminated; Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee

Clinical • Trial completion date • Trial termination • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee (clinicaltrials.gov) - P2; N=259; Active, not recruiting; Sponsor: Regeneron Pharmaceuticals; Recruiting ➔ Active, not recruiting; Trial completion date: Jul 2021 ➔ Feb 2021; Trial primary completion date: Sep 2020 ➔ Apr 2020

Clinical • Enrollment closed • Trial completion date • Trial primary completion date • MRI

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee (clinicaltrials.gov) - P2; N=240; Recruiting; Sponsor: Regeneron Pharmaceuticals; Trial completion date: Mar 2021 ➔ Jul 2021

Clinical • Trial completion date • MRI

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers (clinicaltrials.gov) - P1; N=56; Completed; Sponsor: Regeneron Pharmaceuticals; Active, not recruiting ➔ Completed

Clinical • Trial completion